Skip to main content
Book cover

Sexual Dysfunctions in Mentally Ill Patients pp 153–162Cite as

Sexual Dysfunctions and Substance-Related and Addictive Disorders

  • 792 Accesses

Part of the Trends in Andrology and Sexual Medicine book series (TASM)

Abstract

Substance misuse has a strict relationship with sexual dysfunctions. Psychoactive substances differently affect sexual performances in both sexes, and specific drugs and natural products are often chosen by males and females to enhance their experience and feelings before/during sexual encounters. Moreover, long-term drug users may suffer low libido, erectile dysfunction, and other sexual debilities due to the chronic effects of psychoactives on their body. A further theme of interest for mental health service workers is the intentional practice of sex under the influence of psychoactive substances, known as “chemsex,” and acted mainly among homosexual males. All these issues will be discussed in this chapter.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-68306-5_14
  • Chapter length: 10 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   84.99
Price excludes VAT (USA)
  • ISBN: 978-3-319-68306-5
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   109.99
Price excludes VAT (USA)
Hardcover Book
USD   149.99
Price excludes VAT (USA)
Learn about institutional subscriptions

References

  1. Nair R, Sellaturay S, Sriprasad S. The history of ginseng in the management of erectile dysfunction in ancient China (3500-2600 BCE). Indian J Urol. 2012;28:15–20.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  2. Evans-Brown M, McVeigh J, Perkins C, Bellis M. Human enhancement drugs. The emerging challenges to public health. Liverpool: John Moore; 2012.

    Google Scholar 

  3. Jiann B. Erectile dysfunction associated with psychoactive substances. Chonnam Med J. 2008;44(3):117–24.

    CrossRef  CAS  Google Scholar 

  4. Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, et al. Sex, drugs, and rock “N” roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms. J Psychoactive Drugs [Internet]. 2012;44(1):38–55. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958/.

    CrossRef  Google Scholar 

  5. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14):5274–8.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  6. Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6(6):1506–33.

    CrossRef  CAS  PubMed  Google Scholar 

  7. Bradley KC, Boulware MB, Jiang H, Doerge RW, Meisel RL, Mermelstein PG. Changes in gene expression within the nucleus accumbens and striatum following sexual experience. Genes Brain Behav. 2005;4(1):31–44.

    CrossRef  CAS  PubMed  Google Scholar 

  8. McCall H, Adams N, Mason D, Willis J. What is chemsex and why does it matter? BMJ [Internet]. 2015;351:h5790. http://www.bmj.com/lookup/doi/10.1136/bmj.h5790.

    CrossRef  Google Scholar 

  9. Corazza O, Martinotti G, Santacroce R, Chillemi E, Di Giannantonio M, Schifano F, et al. Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and ginkgo biloba. Biomed Res Int. 2014;2014:13.

    CrossRef  Google Scholar 

  10. Pratap SA, Rajender S. Potent natural aphrodisiacs for the management of erectile dysfunction and male sexual debilities. Front Biosci (Schol Ed). 2012;4:167–80.

    CrossRef  Google Scholar 

  11. Kenyon SL, Button J, Perella P, McKeown DA, Holt DW. An herbal remedy for impotence: more than was bargained for. J Clin Pharmacol. 2006;46:1379–81.

    CrossRef  CAS  PubMed  Google Scholar 

  12. Gonzales GF. Ethnobiology and ethnopharmacology of lepidium meyenii (Maca), a plant from the Peruvian Highlands. Evid Based Complement Alternat Med. 2012;2012:10.

    CrossRef  Google Scholar 

  13. Zheng BL, He K, Kim CH, Rogers L, Shao Y, Huang ZY, et al. Effect of a lipidic extract from lepidium meyenii on sexual behavior in mice and rats. Urology. 2000;55(4):598–602.

    CrossRef  CAS  PubMed  Google Scholar 

  14. Cicero AFG, Piacente S, Plaza A, Sala E, Arletti R, Pizza C. Hexanic Maca extract improves rat sexual performance more effectively than methanolic and chloroformic Maca extracts. Andrologia. 2002;34(3):177–9.

    CrossRef  CAS  PubMed  Google Scholar 

  15. Lee MS, Shin B-C, Yang EJ, Lim H-J, Ernst E. Maca (Lepidium meyenii) for treatment of menopausal symptoms: a systematic review. Maturitas. 2011;70(3):227–33.

    CrossRef  PubMed  Google Scholar 

  16. Shin B-C, Lee MS, Yang EJ, Lim H-S, Ernst E. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med. 2010;10:44.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  17. Piacente S, Carbone V, Plaza A, Zampelli A, Pizza C. Investigation of the tuber constituents of maca (Lepidium meyenii Walp.). J Agric Food Chem. 2002;50(20):5621–5.

    CrossRef  CAS  PubMed  Google Scholar 

  18. Linden CH, Vellman WP, Rumack B. Yohimbine: a new street drug. Ann Emerg Med. 1985;14(10):1002–4.

    CrossRef  CAS  PubMed  Google Scholar 

  19. Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California poison control system reported cases. Ann Pharmacother. 2010;44(6):1022–9.

    CrossRef  PubMed  Google Scholar 

  20. Gass JT, Olive MF. Reinstatement of ethanol-seeking behavior following intravenous self-administration in Wistar rats. Alcohol Clin Exp Res. 2007;31(9):1441–5.

    CrossRef  CAS  PubMed  Google Scholar 

  21. Feltenstein MW, See RE. Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine. Behav Brain Res. 2006;174(1):1–8.

    CrossRef  CAS  PubMed  Google Scholar 

  22. Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry. 2002;51(8):642–51.

    CrossRef  CAS  PubMed  Google Scholar 

  23. Greenwald MK, Lundahl LH, Steinmiller CL. Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals. Psychopharmacology. 2013;225:811–24.

    CrossRef  CAS  PubMed  Google Scholar 

  24. Abad MJ, Bedoya LM, Bermejo P. An update on drug interactions with the herbal medicine Ginkgo biloba. Curr Drug Metab. 2010;11(2):171–81.

    CrossRef  CAS  PubMed  Google Scholar 

  25. Kumar S, Madaan R, Sharma A. Pharmacological evaluation of bioactive principle of Turnera aphrodisiaca. Indian J Pharm Sci. 2008;70(6):740–4.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  26. Arletti R, Benelli A, Cavazzuti E, Scarpetta G, Bertolini A. Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual-behavior of male rats. Psychopharmacology. 1999;143(1):15–9.

    CrossRef  CAS  PubMed  Google Scholar 

  27. Santacroce R, Corazza O, Martinotti G, Bersani FS, Valeriani G, Di Giannantonio M. Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. Hum Psychopharmacol Clin Exp [Internet]. 2015;30(4):265–71. https://doi.org/10.1002/hup.2410.

    CrossRef  Google Scholar 

  28. Martinotti G, Lupi M, Carlucci L, Cinosi E, Santacroce R, Acciavatti T, et al. Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas. Hum Psychopharmacol. 2015;30(4):295–301.

    CrossRef  CAS  PubMed  Google Scholar 

  29. Emboden WA. Transcultural use of narcotic water lilies in ancient Egyptian and Maya drug ritual. J Ethnopharmacol. 1981;3(1):39–83.

    CrossRef  CAS  PubMed  Google Scholar 

  30. Fiorino DF, Phillips a G. Facilitation of sexual behavior in male rats following d-amphetamine-induced behavioral sensitization. Psychopharmacology. 1999;142(2):200–8.

    CrossRef  CAS  PubMed  Google Scholar 

  31. Semple SJ, Patterson TL, Grant I. The context of sexual risk behavior among heterosexual methamphetamine users. Addict Behav. 2004;29(4):807–10.

    CrossRef  PubMed  Google Scholar 

  32. Palha AP, Esteves M. Drugs of abuse and sexual functioning. Adv Psychosom Med. 2008;29:131–49.

    CrossRef  PubMed  Google Scholar 

  33. Degenhardt L, Topp L. “Crystal meth” use among polydrug users in Sydney’s dance party subculture: characteristics, use patterns and associated harms. Int J Drug Policy. 2003;14:17–24.

    CrossRef  Google Scholar 

  34. Rawson RA, Washton A, Domier CP, Reiber C. Drugs and sexual effects: role of drug type and gender. J Subst Abus Treat. 2002;22(2):103–8.

    CrossRef  Google Scholar 

  35. Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol. 2012;7:113–39.

    CrossRef  PubMed  Google Scholar 

  36. Kobayashi H, Ujike H, Iwata N, Inada T, Yamada M, Sekine Y, et al. Association analysis of the tryptophan hydroxylase 2 gene polymorphisms in patients with methamphetamine dependence/psychosis. Curr Neuropharmacol. 2011;9:176–82.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  37. Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. J Psychoactive Drugs. 2001;33(3):223–32.

    CrossRef  CAS  PubMed  Google Scholar 

  38. Gourley M. A subcultural study of recreational ecstasy use. J Sociol. 2004;40(1):59–73.

    CrossRef  Google Scholar 

  39. NIH. HSDB: 3,4-Methylenedioxymethamphetamine [Internet]. US National Library of Medicine. 2008 [cited 2017 Jan 20]. https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@rn+@rel+42542-10-9.

  40. Lyon RA, Glennon RA, Titeler M. 3,4-Methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl) [Internet]. 1986;88(4):525–6. https://doi.org/10.1007/BF00178519.

    CrossRef  CAS  Google Scholar 

  41. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67–85.

    CrossRef  CAS  PubMed  Google Scholar 

  42. McElrath K. MDMA and sexual behavior: ecstasy users’ perceptions about sexuality and sexual risk. Subst Use Misuse. 2005;6084:1461–77.

    CrossRef  Google Scholar 

  43. Zemishlany Z, Aizenberg D, Weizman A. Subjective effects of MDMA (“ecstasy”) on human sexual function. Eur Psychiatry. 2001;16(2):127–30.

    CrossRef  CAS  PubMed  Google Scholar 

  44. Breslau K. The “sextasy” craze. Clubland’s dangerous party mix: Viagra and ecstasy. Newsweek. 2002;139:30.

    PubMed  Google Scholar 

  45. Tran QT, Wallace RA, Sim EHA. Priapism, ecstasy, and marijuana: is there a connection? Adv Urol. 2008;2008:193694.

    PubMed Central  Google Scholar 

  46. Romanelli F, Smith KM, Thornton AC, Pomeroy C. Poppers: epidemiology and clinical management of inhaled nitrite abuse. Pharmacotherapy. 2004;24(1):69–78.

    CrossRef  PubMed  Google Scholar 

  47. Lampinen TM, Mattheis K, Chan K, Hogg RS. Nitrite inhalant use among young gay and bisexual men in Vancouver during a period of increasing HIV incidence. BMC Public Health. 2007;7:35.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  48. Gruener AM, Jeffries MAR, El Housseini Z, Whitefield L. Poppers maculopathy. Lancet. 2014;384(9954):1606.

    CrossRef  PubMed  Google Scholar 

  49. Romanelli F, Smith KM. Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males. Ann Pharmacother [Internet]. 2004;38(6):1024–30. https://doi.org/10.1345/aph.1D571.

    CrossRef  CAS  Google Scholar 

  50. Stalnikowicz R, Amitai Y, Bentur Y. Aphrodisiac drug-induced Hemolysis. J Toxicol Clin Toxicol [Internet]. 2004;42(3):313–6. https://doi.org/10.1081/CLT-120037435.

    CrossRef  CAS  Google Scholar 

  51. Hagan IG, Burney K. Radiology of recreational drug abuse. RadioGraphics [Internet]. 2007;27(4):919–40. https://doi.org/10.1148/rg.274065103.

    CrossRef  Google Scholar 

  52. Grover S, Mattoo SK, Pendharkar S, Kandappan V. Sexual dysfunction in patients with alcohol and opioid dependence. Indian J Psychol Med. 2014;36:355–65.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  53. Alcohol use and sexual risk behaviour: a cross-cultural study in eight countries. Geneva: World Health Organization; 2005. p. 148.

    Google Scholar 

  54. Arackal BS, Benegal V. Prevalence of sexual dysfunction in male subjects with alcohol dependence. Indian J Psychiatry [Internet]. 2007;49(2):109–12. http://www.ncbi.nlm.nih.gov/pubmed/20711392.

    CrossRef  Google Scholar 

  55. Zaazaa A, Bella AJ, Shamloul R. Drug addiction and sexual dysfunction. Endocrinol Metab Clin N Am. 2013;42(3):585–92.

    CrossRef  Google Scholar 

  56. Amoako AA, Marczylo TH, Marczylo EL, Elson J, Willets JM, Taylor AH, et al. Anandamide modulates human sperm motility: implications for men with asthenozoospermia and oligoasthenoteratozoospermia. Hum Reprod. 2013;28(8):2058–66.

    CrossRef  CAS  PubMed  Google Scholar 

  57. Aversa A, Rossi F, Francomano D, Bruzziches R, Bertone C, Santiemma V, et al. Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users. Int J Impot Res. 2008;20(6):566–73.

    CrossRef  CAS  PubMed  Google Scholar 

  58. Pake JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manag. 1994;9(2):126–31.

    CrossRef  Google Scholar 

  59. Bourne A, Reid D, Hickson F, Torres-Rueda S, Weatherburn P. Illicit drug use in sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect [Internet]. 2015;91(8):564–8. http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=CitingArticles&qid=1&SID=W1HnFq71TOmNoSHorBF&page=1&doc=1&cacheurlFromRightClick=no.

    CrossRef  CAS  Google Scholar 

  60. Race K. “Party ‘n’ play”: online hook-up devices and the emergence of PNP practices among gay men. Sexualities. 2015:1–40.

    Google Scholar 

  61. Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardo FP. When “chems” meet sex: a rising phenomenon called “ChemSex”. Curr Neuropharmacol. 2016;15(5):762–70.

    Google Scholar 

  62. Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14(1):15–26.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  63. Winstock AR, Marsden J, Mitcheson L. What should be done about mephedrone? BMJ. 2010;340:c1605.

    CrossRef  PubMed  Google Scholar 

  64. Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am. 2014;32(1):1–28.

    CrossRef  PubMed  Google Scholar 

  65. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al. Mephedrone (4-methylmethcathinone; “meow meow”): chemical, pharmacological and clinical issues. Psychopharmacology. 2011;214(3):593–602.

    CrossRef  CAS  PubMed  Google Scholar 

  66. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 2011;28(4):280–2.

    CrossRef  CAS  PubMed  Google Scholar 

  67. Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom. J Clin Psychopharmacol. 2012;32(5):710–4.

    CrossRef  CAS  PubMed  Google Scholar 

  68. Emcdda. Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone) In accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances. EMCDDA Risk Assessments. 2011.

    Google Scholar 

  69. Newcombe R. Mephedrone: the use of mephedrone (M-cat, Meow) in Middlesbrough. Manchester: Lifeline Publications and Research; 2009. p. 1–16.

    Google Scholar 

  70. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol [Internet]. 2012;50(6):458–70. https://doi.org/10.3109/15563650.2012.702218.

    CrossRef  CAS  Google Scholar 

  71. Vickers MD. Gamma hydroxybutyric acid. Clinical pharmacology and current status. Proc R Soc Med [Internet]. 1968;61(8):821–4. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1902450&tool=pmcentrez&rendertype=abstract.

    CAS  Google Scholar 

  72. Sumnall HR, Beynon CM, Conchie SM, Riley SCE, Cole JC. An investigation of the subjective experiences of sex after alcohol or drug intoxication. J Psychopharmacol [Internet]. 2007;21(5):525–37. https://doi.org/10.1177/0269881106075590.

    CrossRef  CAS  Google Scholar 

  73. Brewster VL, Edwards HGM, Hargreaves MD, Munshi T. Identification of the date-rape drug GHB and its precursor GBL by Raman spectroscopy. Drug Test Anal. 2009;1(1):25–31.

    CrossRef  CAS  PubMed  Google Scholar 

  74. Barker JC, Harris SL, Dyer JE. Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study. J Psychoactive Drugs. 2007;39:115–29.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  75. Abdulrahim D, Bowden-Jones O. Guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive substances. 2015. 335 p. http://www.drugsandalcohol.ie/24292/.

  76. Corkery JM, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD, BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev. 2015;53:52–78.

    CrossRef  CAS  PubMed  Google Scholar 

  77. Hockenhull J, Murphy KG, Paterson S. An observed rise in γ-hydroxybutyrate-associated deaths in London: evidence to suggest a possible link with concomitant rise in chemsex. Forensic Sci Int [Internet]. 2017;270:93–7. https://doi.org/10.1016/j.forsciint.2016.11.039.

    CrossRef  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. “G.d’Annunzio” University, Department of Neuroscience, Imaging and Clinical Sciences, Chieti, Italy

    Giovanni Martinotti, Emanuela Belfiglio, Rita Santacroce & Massimo di Giannantonio

Authors
  1. Giovanni Martinotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emanuela Belfiglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rita Santacroce
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Massimo di Giannantonio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Martinotti .

Editor information

Editors and Affiliations

  1. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

    Prof. Emmanuele A. Jannini

  2. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

    Alberto Siracusano

Rights and permissions

Reprints and Permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Martinotti, G., Belfiglio, E., Santacroce, R., di Giannantonio, M. (2018). Sexual Dysfunctions and Substance-Related and Addictive Disorders. In: Jannini, E., Siracusano, A. (eds) Sexual Dysfunctions in Mentally Ill Patients. Trends in Andrology and Sexual Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-68306-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68306-5_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68305-8

  • Online ISBN: 978-3-319-68306-5

  • eBook Packages: MedicineMedicine (R0)